$6.39
0.050.79%
Cartesian Therapeutics (RNAC) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.68 | $-0.73 | $-0.80 | $-0.70 |
| Actual | $0.46 | $-1.46 | $-1.39 | $-1.38 |
| Surprise | +167.7% | -100.0% | -73.8% | -97.1% |
| Revenue | ||||
| Estimate | $162912 | $205912 | $212132 | $226536 |
| Actual | $0 | $78000 | $947000 | $452000 |
| Surprise | -100.0% | -62.1% | +346.4% | +99.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.01 | $-1.05 | $-1.13 | $-0.99 |
| Revenue | ||||
| Consensus | $147144 | $238568 | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $0.46 | $-0.68 | 167.7 % |
| Q1 | Apr 30, 2026 | $-1.46 | $-0.73 | -100.0 % |
| Q4 | Mar 9, 2026 | $-1.39 | $-0.80 | -73.8 % |
| Q3 | Nov 6, 2025 | $-1.38 | $-0.70 | -97.1 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $0 | $162.91K | -100.0 % |
| Q1 | Apr 30, 2026 | $78.00K | $205.91K | -62.1 % |
| Q4 | Mar 9, 2026 | $947.00K | $212.13K | 346.4 % |
| Q3 | Nov 6, 2025 | $452.00K | $226.54K | 99.5 % |